A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/22/2011	US20110312928 Progesterone Containing Oral Dosage Forms and Related Methods
12/22/2011	US20110312927 Progesterone Containing Oral Dosage Forms and Related Methods
12/22/2011	US20110312926 2-(N-Substituted Piperazinyl) Steroid Derivatives
12/22/2011	US20110312925 Methods of treating or preventing estrogen-related diseases
12/22/2011	US20110312924 Novel steroidal cyp17 inhibitors/antiandrogens
12/22/2011	US20110312923 Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis
12/22/2011	US20110312922 EDTA Resistant S100A12 Complexes (ERAC)
12/22/2011	US20110312921 N-Myristoyl Transferase Inhibitors
12/22/2011	US20110312920 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
12/22/2011	US20110312919 Inhibitors of tyrosine kinase receptor dimerization
12/22/2011	US20110312918 Method for identifying agents for inhibiting cell motility and invasiveness
12/22/2011	US20110312916 Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
12/22/2011	US20110312915 Novel cosmetic compositions
12/22/2011	US20110312914 Carbon monoxide removal agent
12/22/2011	US20110312913 Method and pharmaceutical to treat spinal discs
12/22/2011	US20110312912 Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
12/22/2011	US20110312911 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
12/22/2011	US20110312910 Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof
12/22/2011	US20110312909 Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent
12/22/2011	US20110312908 Small molecule myristate inhibitors of bcr-abl and methods of use
12/22/2011	US20110312907 Polymorphisms predictive of anthracycline- induced cardiotoxicity
12/22/2011	US20110312906 Treatment or reduction of menopausal symptoms
12/22/2011	US20110312905 Stimulus-triggered prodrugs
12/22/2011	US20110312904 Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
12/22/2011	US20110312903 Fluorination of organic compounds
12/22/2011	US20110312897 Cathepsin l proteolytically processes histone h3 during mouse embryonic stem cell differentiation
12/22/2011	US20110312894 Methods of diagnosing and treating neurodegenerative diseases
12/22/2011	US20110312890 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements
12/22/2011	US20110312887 Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
12/22/2011	US20110312885 Controlled release system and manufacturing method thereof
12/22/2011	US20110312882 Methods and compositions for increasing the anaerobic working capacity in tissues
12/22/2011	US20110312880 Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
12/22/2011	US20110312876 Method of determining types I, II, III, IV or V or methicillin-resistant staphylococcus aureus (MRSA) in a biological sample
12/22/2011	US20110312875 Peptidic compounds
12/22/2011	US20110312093 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
12/22/2011	US20110311762 Room temperature stable agarose solutions
12/22/2011	US20110311655 Further preparations of silk proteins, seed oils, monosaccharide, natural botanicals and polysaccharide mixtures in compositions for hair care or hair repair, and skin care and topical treatments
12/22/2011	US20110311654 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders
12/22/2011	US20110311652 Novel Saponin Compounds, Methods of Preparation Thereof, Use Thereof and Pharmaceutical Compositions
12/22/2011	US20110311651 Cardenolides for the treatment of ocular cancer
12/22/2011	US20110311650 Multiplexed biomarkers of insulin resistance
12/22/2011	US20110311648 Novel Methods for the Treatment of Cancer
12/22/2011	US20110311637 Methods and medicaments for administration of ibuprofen
12/22/2011	US20110311636 Methods and medicaments for administration of ibuprofen
12/22/2011	US20110311634 Formulations for animal feed comprising butyrate salt
12/22/2011	US20110311633 Combination of a Silicon Containing Component and a Hormone
12/22/2011	US20110311632 Stable chitosan hemostatic external patch and methods of manufacture
12/22/2011	US20110311631 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
12/22/2011	US20110311629 Non-adhesive elastic gelatin matrices
12/22/2011	US20110311628 Pulsatile release composition of therapeutic agent
12/22/2011	US20110311627 Controlled release levetiracetam formulations and methods for producing the same
12/22/2011	US20110311626 Controlled release compositions comprising anti-cholinergic drugs
12/22/2011	US20110311625 Solid dosage forms of fenofibrate
12/22/2011	US20110311624 Formulations of histone deacetylase inhibitor and uses thereof
12/22/2011	US20110311623 Composition for manufacturing orally disintegrating dosage form to protect coating layer of active substance
12/22/2011	US20110311620 Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
12/22/2011	US20110311619 Pharmaceutical formulation of nanonised fenofibrate
12/22/2011	US20110311618 Inhalable particles comprising tiotropium
12/22/2011	US20110311616 Targeting tumor associated macrophages using bisphosphonate-loaded particles
12/22/2011	US20110311613 Topical formulations of flap inhibitors for the treatment of dermatological conditions
12/22/2011	US20110311610 Temperature reducing, healing wound dressing
12/22/2011	US20110311608 Stable chitosan hemostatic implant and methods of manufacture
12/22/2011	US20110311605 Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings
12/22/2011	US20110311596 Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
12/22/2011	US20110311594 Controlled release compositions with reduced food effect
12/22/2011	US20110311593 N-hydroxylated amidine-, guanidine- and/or aminohydrazone-type prodrugs for application on the skin
12/22/2011	US20110311592 Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
12/22/2011	US20110311591 Antimicrobial Coating
12/22/2011	US20110311584 Use of flt3 ligand for enhancing immune responses in rna immunization
12/22/2011	US20110311583 Novel lipids and compositions for the delivery of therapeutics
12/22/2011	US20110311582 Novel lipids and compositions for the delivery of therapeutics
12/22/2011	US20110311562 Glycolipid Mixture with Anti-Inflammatory Activity Obtained from Oscillatoria Planktothrix
12/22/2011	US20110311560 Methods and Compositions Relating to CCR5 Antagonist, IFN-Gamma and IL-13 Induced Inflammation
12/22/2011	US20110311545 Family of pain producing substances and methods to produce novel analgesic drugs
12/22/2011	US20110311541 Mutant proteins of the f protein of piv-5 and piv-2
12/22/2011	US20110311533 Regulation of protein level
12/22/2011	US20110311531 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/22/2011	US20110311528 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis
12/22/2011	US20110311525 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
12/22/2011	US20110311523 Platelet derived growth factor receptor supports cytomegalovirus infectivity
12/22/2011	US20110311521 Novel therapy for anxiety
12/22/2011	US20110311519 Methods of treatment of bone degenerative diseases
12/22/2011	US20110311518 Novel synthetic agonists of tlr9
12/22/2011	US20110311516 Chemically Programmed Vaccination
12/22/2011	US20110311512 Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets
12/22/2011	US20110311508 Method of modulating hsf-1
12/22/2011	US20110311504 Coenzyme q10-containing composition for oral ingestion
12/22/2011	US20110311503 Active ingredient combinations having insecticidal and acaricidal properties
12/22/2011	US20110311486 1,2,4-oxadiazole benzoic acid compositions
12/22/2011	US20110311485 1,2,4-oxadiazole derivatives and their therapeutic use
12/22/2011	US20110311483 Crth2 modulators
12/22/2011	US20110311482 Hepatitis C Virus Inhibitors
12/22/2011	US20110311480 Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
12/22/2011	US20110311479 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
12/22/2011	US20110311478 Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
12/22/2011	US20110311477 Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies
12/22/2011	US20110311476 Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation
12/22/2011	US20110311474 Novel Tricyclic Compounds
12/22/2011	US20110311472 Application of mrna for use as a therapeutic against tumour diseases
12/22/2011	US20110311467 Longwearing, transfer resistant cosmetic compositions having a unique creamy texture and feel

1 ... 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 ... 7860